Nelmar Valentina Ortiz Cabrera

Nelmar Valentina Ortiz Cabrera

Auto-generated profile, based on publicly available information

Nelmar Valentina Ortiz Cabrera

Department of Genetics Hospital Infantil Universitario Niño Jesús Madrid Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2016 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
NONelmar Valentina Ortiz-Cabrera
Nelmar Valentina Ortiz-Cabrera
RRRosa Riveiro-Álvarez
Rosa Riveiro-Álvarez
MLMiguel Ángel López-Martínez
Miguel Ángel López-Martínez
PPPilar Pérez-Segura
Pilar Pérez-Segura
IAIsabel Aragón-Gómez
Isabel Aragón-Gómez
LSLeandro Soriano-Guillén
Leandro Soriano-Guillén
Background/Aims: Idiopathic central precocious puberty (ICPP) is the premature activation of the hypothalamic-pituitary-gonadal axis in the absence of organic disease. Up to now, just gain-of-function mutations of KISS1/KISS1R and loss-of-function mutations of the maternally imprinted gene MKRN3 are the known genetic causes of ICPP. Our intention is to evaluate variants present in genes related to the pubertal onset pathway that could act as disease-causing or predisposing variants. Methods: We studied the clinical exome of 20 patients diagnosed with ICPP using the Illumina platform. The bioinformatics analysis was performed using 2 different programs, and the variants were filtered according to a list of genes related to the gonadotropin-releasing hormone pathway. Results: In a “sporadic case,” we found a missense variant in MKRN3 NM_005664.3: c.203G>A, causing the protein change NP_005655.1:p.Arg68His, predicted as pathogenic by 2 informatics tools. The proband carrying this variant was diagnosed with ICPP at 7.75 years of age. We did not find any pathogenic variants in KISS1, KISS1R, LIN28, GNRH, GNRHR, TACR3, and TAC3. Conclusion:MKRN3 is the most frequent genetic cause of familial ICPP, so it is wise to screen for MKRN3 mutations in all patients with familial ICPP and in patients with an unclear paternal pubertal history.

18 September 2019 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
MGMaría Güemes
María Güemes
ÁRÁlvaro Martín Rivada
Álvaro Martín Rivada
NONeimar Valentina Ortiz-Cabrera
Neimar Valentina Ortiz-Cabrera
GMGabriel Angel Martos Moreno
Gabriel Angel Martos Moreno
JPJesús Pozo-Román
Jesús Pozo-Román
JAJesús Argente
Jesús Argente
Background: LZTR1 participates in RAS protein degradation, hence limiting the RAS/MAPK cascade. Pathogenic mutations in LZTR1 (MIM:600574) have been described in a few patients with Noonan syndrome (NS). Three patients with LZTR1 mutations of different genetic transmission and NS phenotype are herein characterized. Clinical Cases: Case 1 is a 5-year-old boy with NS phenotype. Sanger sequencing of PTPN11 and SOS1 identified no mutations. Whole exome sequencing (WES) detected a heterozygous missense mutation in LZTR1:c.742G>A (p.Gly248Arg) (exon 8, Kelch 4 functional domain). Bioinformatic algorithms predict a deleterious effect of this variant, previously described to cause NS. Case 2 is a 4-year-old boy with NS phenotype. Direct sequencing of 8 genes associated with NS identified no mutations. WES localized a homozygous missense mutation in LZTR1:c.2074T>C (p.Phe692Leu, exon 18). This mutation has not been reported before and is predicted to have a deleterious effect on the protein. Case 3 is an 8-year-old boy who shares NS phenotype with his mother. A multigene panel for RASopathies showed a heterozygous missense variant in LZTR1:c.730T>C (p.Ser244Pro) (exon 8; Kelch 4 functional domain) that was maternally inherited. This variant has not been previously described; however, in silico predictors classify it as deleterious. Familial segregation suggests its pathogenicity. Conclusions: The molecular approach for syndromic phenotypes associated with various genes should involve complete/updated panels or WES rather than gene-by-gene sequencing. RASopathy genetic panels should incorporate LZTR1. Patients with pathogenic mutations in LZTR1 exhibit a characteristic NS gestalt but variable cardiac, height, and neurodevelopment expressions, with recessive inheritance possibly associating with a more severe phenotype.

19 August 2023 in Epileptic Disorders
Verified
Journal Article
Closed access
MPMaria Ballarà Petitbò
Maria Ballarà Petitbò
EAElena González Alguacil
Elena González Alguacil
EDEva Gutiérrez Delicado
Eva Gutiérrez Delicado
NCNelmar Valentina Ortiz Cabrera
Nelmar Valentina Ortiz Cabrera
ARAnna Duat Rodríguez
Anna Duat Rodríguez
VIVictor Soto Insuga
Victor Soto Insuga

1 January 2020 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
ÁMÁlvaro Martín-Rivada
Álvaro Martín-Rivada
JPJesús Pozo-Román
Jesús Pozo-Román
MGMaría Güemes
María Güemes
NONelmar Valentina Ortiz-Cabrera
Nelmar Valentina Ortiz-Cabrera
LJLuis Alberto Pérez Jurado
Luis Alberto Pérez Jurado
JAJesús Argente
Jesús Argente
Introduction: Primary autosomal recessive microcephalies (MCPHs) are characterized by primary dwarfism with MCPH and may present delayed psychomotor development and visual impairment. Biallelic loss of function variants in the PLK4 gene, which encodes the polo-like kinase 4 protein involved in centriole biogenesis, has been recently identified in several patients with MCPH and various ethnic backgrounds. Case Presentation: Here, we describe 2 siblings of different sex from Equatorial Guinea harboring a homozygous frameshift mutation in PLK4 (c.1299_1303del, p.Phe433Leufs*6). A Seckel syndrome spectrum phenotype was present in both siblings, with short stature, severe MCPH, reduced brain volume, and distinctive facial features. They also presented severe intellectual disability, lissencephaly/pachygyria, subependymal heterotopia, and ophthalmological impairment. One of them suffered from deafness, and scoliosis was observed in the other. Discussion/Conclusion: Biallelic variants in PLK4 lead to a syndrome where severe short stature, MCPH, and cognitive impairment are constant features. However, ocular, skeletal, and other neurological manifestations can vary upon the same genetic basis.

1 June 2017 in Clinical Biochemistry
Verified
Journal Article
Closed access
MTMaría Josefa Torrejón
María Josefa Torrejón
NON. Valentina Ortíz-Cabrera
N. Valentina Ortíz-Cabrera
JNJorge Martínez Nieto
Jorge Martínez Nieto
FFFernando-Ataúlfo González Fernández
Fernando-Ataúlfo González Fernández
AVAna Villegas
Ana Villegas
PRPaloma Ropero
Paloma Ropero

1 December 2016 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
NON.V. Ortiz-Cabrera
N.V. Ortiz-Cabrera
JGJ. Gallego-Merlo
J. Gallego-Merlo
CVC. Vélez-Monsalve
C. Vélez-Monsalve
RNR. de Nicolas
R. de Nicolas
SMSebastian Mas-Fontao
Sebastian Mas-Fontao
MTM.J. Trujillo-Tiebas
M.J. Trujillo-Tiebas
Fundación Jiménez Díaz (FJD) is a reference center for genetic diagnosis of Gaucher disease (GD) in Spain. Genetic analyses of acid β-glucosidase (GBA) gene using different techniques were performed to search for new mutations, in addition to those previously and most frequently found in the Spanish population. Additionally, the study of the chitotriosidase (CHIT1) gene was used to assess the inflammatory status of patients in the follow-up of enzyme replacement therapy (ERT). We present the genetic data gathered during the last nine years at FJD. Blood samples from patients with suspected GD were collected for enzymatic and genetic analyses. The genetic analysis was performed on DNA from 124 unrelated suspected cases and 57 relatives from 2007 to 2015, starting with a mutational screening kit, followed by Sanger sequencing of the entire gene and other techniques to look for deletions. CHIT1 was also studied to assess the reliability of this biomarker. In 46 out of 93 GD patients (49.5%) the two mutant alleles were found. We detected 21 different mutations. The most common mutation was N370S (c.126A > G; p.Asp409Ser current nomenclature) (in 50.5% of patients), followed by L444P (c.1448T > C; p.Leu483Pro current nomenclature) (in 24.7%). The most common heterozygous compound genotype observed (18.3%) was c.1226A > G/c.1448T > C (N370S/L444P). Two novel mutations were found (del. Ex.4-11 and c.1296G > T; pW432C), as well as p.S146L, only once previously reported. Two patients showed the homozygous state for the duplication of CHIT1. N370S and L444P are the most common mutations and other mutations associated to Parkinson's disease have been observed. This should be taken into account in the genetic counseling of GD patients.